Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBT001
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : RA Capital Management
Deal Size : $90.0 million
Deal Type : Series A Financing
I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
Details : The proceeds will be used to advance next-generation bispecific antibodies, including BBT001, for immunology & inflammation diseases, including moderate to severe Atopic Dermatitis.
Product Name : BBT001
Product Type : Antibody
Upfront Cash : Undisclosed
February 14, 2025
Lead Product(s) : BBT001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : RA Capital Management
Deal Size : $90.0 million
Deal Type : Series A Financing
Reset All
